DRIO - DarioHealth Corp Stock Price, Fair Value and News

1.42USD-0.06 (-4.05%)Market Closed

Market Summary

USD1.42-0.06

Market Closed

-4.05%

DRIO Stock Price

View Fullscreen

DRIO RSI Chart

DRIO Valuation

Market Cap

41.8M

Price/Earnings (Trailing)

-0.7

Price/Sales (Trailing)

2.05

EV/EBITDA

-0.54

Price/Free Cashflow

-1.35

DRIO Price/Sales (Trailing)

DRIO Profitability

Operating Margin

86.66%

EBT Margin

-290.64%

Return on Equity

-102.21%

Return on Assets

-61.65%

Free Cashflow Yield

-74.06%

DRIO Fundamentals

DRIO Revenue

Revenue (TTM)

20.4M

Rev. Growth (Yr)

-46.89%

Rev. Growth (Qtr)

2.79%

DRIO Earnings

Earnings (TTM)

-59.4M

Earnings Growth (Yr)

-13.22%

Earnings Growth (Qtr)

9.2%

Breaking Down DRIO Revenue

Last 7 days

-2.1%

Last 30 days

-7.2%

Last 90 days

-24.9%

Trailing 12 Months

-56.0%

How does DRIO drawdown profile look like?

DRIO Financial Health

Current Ratio

3.79

Debt/Equity

0.42

Debt/Cashflow

-1.24

DRIO Investor Care

Shares Dilution (1Y)

13.79%

Diluted EPS (TTM)

1.93

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	26.7M	26.6M	23.5M	20.4M
2022	25.0M	25.9M	26.9M	27.7M
2021	9.5M	13.0M	16.6M	20.5M
2020	7.0M	7.1M	7.3M	7.6M
2019	7.9M	7.5M	7.5M	7.6M
2018	5.9M	6.8M	7.3M	7.4M
2017	3.2M	3.8M	4.4M	5.2M
2016	1.3M	1.8M	2.3M	2.8M
2015	244.0K	437.0K	630.0K	823.0K
2014	0	0	0	51.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of DarioHealth Corp

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 06, 2024	shaked yoav	acquired	-	-	90,000	-
Mar 06, 2024	stern adam k	acquired	-	-	70,000	-
Mar 06, 2024	ben-david zvi	acquired	-	-	400,000	chief financial officer
Mar 06, 2024	kaplan jon h.	acquired	-	-	70,000	-
Mar 06, 2024	mcgrath dennis m	acquired	-	-	80,000	-
Mar 06, 2024	matheis dennis	acquired	-	-	70,000	-
Mar 06, 2024	karah hila	acquired	-	-	70,000	-
Mar 06, 2024	raphael erez	acquired	-	-	800,000	chief executive officer
Jan 13, 2023	raphael erez	sold	-7,449	6.2075	-1,200	chief executive officer
Dec 21, 2022	mcgrath dennis m	sold	-39,205	3.9714	-9,872	-

Which funds bought or sold DRIO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 26, 2024	First Horizon Advisors, Inc.	sold off	-100	-645	-	-%
Apr 25, 2024	SIMPLEX TRADING, LLC	added	5.16	-1,000	7,000	-%
Mar 11, 2024	VANGUARD GROUP INC	added	20.21	-366,154	624,432	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	182	118,144	362,288	-%
Feb 20, 2024	Clarity Capital Partners LLC	new	-	293,133	293,133	0.21%
Feb 15, 2024	Nantahala Capital Management, LLC	added	93.58	119,881	8,038,430	0.24%
Feb 14, 2024	STATE STREET CORP	unchanged	-	-117,558	129,616	-%
Feb 14, 2024	BANK OF AMERICA CORP /DE/	reduced	-13.55	-51,889	43,034	-%
Feb 14, 2024	Appian Way Asset Management LP	added	2.52	-1,956,580	2,274,600	0.48%
Feb 14, 2024	Walleye Capital LLC	sold off	-100	-3,967,630	-	-%

Are Funds Buying or Selling DRIO?

Are funds buying DRIO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own DRIO

No. of Funds

Unveiling DarioHealth Corp's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	nantahala capital management, llc	9.9%	2,761,140	SC 13G/A
Feb 06, 2024	y.d. more investments ltd	4.73%	1,288,518	SC 13G/A
Sep 08, 2023	kershner trading americas,llc	3.87%	1,053,024	SC 13G/A
Feb 14, 2023	phoenix holdings ltd.	5.22%	1,341,027	SC 13G/A
Feb 14, 2023	collaborative holdings management lp	0%	0	SC 13G/A
Feb 14, 2023	nantahala capital management, llc	9.9%	2,576,318	SC 13G/A
Feb 13, 2023	y.d. more investments ltd	5.91%	1,518,025	SC 13G/A
Feb 13, 2023	clal insurance enterprises holdings ltd	4.2%	1	SC 13G/A
May 18, 2022	kershner trading americas,llc	5.6%	0	SC 13G
Mar 14, 2022	phoenix holdings ltd.	6.12%	1,341,027	SC 13G/A

Recent SEC filings of DarioHealth Corp

View All Filings

Date Filed	Form Type	Document
Apr 22, 2024	8-K	Current Report
Apr 22, 2024	S-3	S-3
Apr 19, 2024	424B3	Prospectus Filed
Apr 19, 2024	8-K	Current Report
Apr 19, 2024	PRE 14A	PRE 14A
Apr 05, 2024	8-K	Current Report
Mar 28, 2024	10-K	Annual Report
Mar 08, 2024	4	Insider Trading
Mar 08, 2024	4	Insider Trading
Mar 08, 2024	4	Insider Trading

Peers (Alternatives to DarioHealth Corp)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
DHR	182.7B	23.7B	-1.24%	2.02%	41.5	7.7	-8.94%	-35.72%
IDXX	40.9B	3.7B	-8.74%	0.65%	48.45	11.18	8.72%	24.44%
A	40.2B	6.7B	-5.82%	0.71%	32.49	5.96	-2.81%	-6.58%
DGX	15.4B	9.3B	3.81%	-0.93%	18.14	1.65	-3.29%	6.68%
MEDP	12.0B	2.0B	-3.91%	88.07%	38.5	6.13	25.57%	21.62%
CRL	11.8B	4.1B	-15.48%	20.46%	24.78	2.85	3.86%	-2.39%
NTRA	11.2B	1.1B	1.55%	76.98%	-25.8	10.36	31.99%	20.63%
EXAS	10.8B	2.5B	-14.06%	-6.40%	-52.77	4.31	19.93%	67.26%
MID-CAP
NEOG	2.7B	929.2M	-21.86%	-28.69%	1.7K	2.87	28.93%	111.61%
GH	2.2B	563.9M	-12.75%	-20.04%	-4.57	3.88	25.45%	26.76%
SMALL-CAP
CDNA	401.8M	280.3M	-26.72%	-6.51%	-2.11	1.43	-12.89%	-148.37%
ACRS	85.8M	31.2M	-2.42%	-86.92%	-0.97	2.75	5.03%	-1.81%
APDN	67.9M	9.0M	875.61%	304.04%	-9.4	7.55	-53.31%	2.21%
AWH	39.7M	9.2M	3.87%	-30.75%	-2.38	4.34	11.85%	44.12%
BIOC	183.8K	25.9M	-50.00%	-94.83%	-0.01	0.01	-57.78%	-93.11%

DarioHealth Corp News

Latest updates

DarioHealth Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	2.8%	3,616,000	3,518,000	6,152,000	7,066,000	6,809,000	6,605,000	6,183,000	8,059,000	6,028,000	5,629,000	5,261,000	3,595,000	2,080,000	2,042,000	1,787,000	1,667,000	1,798,000	1,868,000	1,651,000	2,242,000	1,700,000
Gross Profit	-78.4%	132,000	610,000	2,074,000	3,168,000	2,732,000	1,800,000	1,138,000	3,985,000	548,000	826,000	1,508,000	1,081,000	549,000	549,000	636,000	779,000	840,000	873,000	326,000	558,000	223,000
Operating Expenses	-11.2%	14,347,000	16,156,000	16,094,000	15,576,000	11,742,000	16,373,000	18,493,000	19,857,000	22,213,000	23,325,000	19,511,000	15,408,000	9,613,000	7,151,000	4,759,000	10,893,000	5,021,000	3,672,000	5,688,000	5,921,000	5,149,000
S&GA Expenses	33.9%	5,529,000	4,128,000	4,412,000	4,071,000	3,040,000	3,999,000	5,059,000	4,395,000	4,667,000	7,123,000	6,121,000	5,621,000	3,297,000	2,562,000	1,326,000	5,571,000	1,858,000	948,000	1,704,000	973,000	962,000
R&D Expenses	-25.9%	4,196,000	5,665,000	5,222,000	5,165,000	4,782,000	4,803,000	4,137,000	5,927,000	5,316,000	5,506,000	3,742,000	2,655,000	1,423,000	954,000	825,000	1,231,000	840,000	859,000	991,000	1,002,000	927,000
EBITDA Margin	-Infinity%	-2.69	-	-2.28	-2.46	-2.37	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	0.5%	996,000	991,000	972,000	1,072,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Income Taxes	-	-	-	-	-	3,000	-	1,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	9.6%	-14,221,000	-15,732,000	-16,585,000	-	-12,614,000	-15,632,000	-18,027,000	-	-21,554,000	-22,444,000	-17,765,000	-	-	-	-	-	-	-	-	-	-
EBT Margin	-13.0%	-2.91	-2.57	-2.36	-2.54	-2.45	-2.89	-3.08	-3.07	-3.74	-1.78	-2.27	-3.10	-	-	-	-	-	-	-	-	-
Net Income	9.2%	-14,285,000	-15,732,000	-16,585,000	-12,825,000	-12,617,000	-15,632,000	-18,028,000	-15,916,000	-21,586,000	-22,444,000	-17,765,000	-14,966,000	-8,997,000	-6,550,000	-4,006,000	-9,892,000	-4,173,000	-2,805,000	-5,382,000	-5,376,000	-4,983,000
Net Income Margin	-19.0%	-2.92	-2.45	-2.17	-2.22	-2.25	-2.65	-3.01	-3.11	-3.74	-3.87	-3.72	-3.63	-	-	-	-	-	-	-	-	-
Free Cashflow	16.8%	-7,424,000	-8,926,000	-9,782,000	-4,831,000	-7,984,000	-10,869,000	-11,274,000	-18,160,000	-15,204,000	-12,531,000	-12,335,000	-10,600,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-9.5%	96.00	107	117	108	119	126	137	127	101	117	131	124	35.00	41.00	17.00	20.00	25.00	9.00	12.00	11.00	14.00
Current Assets	-15.8%	47.00	56.00	66.00	55.00	66.00	72.00	82.00	71.00	46.00	59.00	72.00	88.00	34.00	40.00	16.00	18.00	23.00	7.00	11.00	10.00	13.00
Cash Equivalents	-16.1%	37.00	44.00	53.00	39.00	49.00	57.00	68.00	56.00	36.00	51.00	64.00	81.00	29.00	37.00	13.00	16.00	21.00	5.00	8.00	7.00	11.00
Inventory	-7.5%	5.00	5.00	6.00	7.00	8.00	8.00	8.00	8.00	6.00	4.00	5.00	5.00	2.00	2.00	1.00	1.00	1.00	1.00	2.00	2.00	1.00
Net PPE	-10.0%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Goodwill	0%	42.00	42.00	42.00	42.00	42.00	42.00	42.00	42.00	42.00	39.00	39.00	25.00	-	-	-	-	-	-	-	-	-
Current Liabilities	54.1%	12.00	8.00	8.00	18.00	19.00	12.00	13.00	13.00	14.00	13.00	13.00	12.00	7.00	6.00	5.00	4.00	5.00	4.00	6.00	7.00	5.00
Long Term Debt	-15.2%	25.00	29.00	29.00	17.00	18.00	24.00	23.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Current	-	4.00	-	-	-	9.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-15.2%	25.00	29.00	29.00	17.00	18.00	24.00	23.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	-14.5%	58.00	68.00	78.00	72.00	80.00	89.00	100	114	86.00	104	118	112	28.00	35.00	12.00	15.00	19.00	4.00	6.00	4.00	9.00
Retained Earnings	-4.6%	-349	-333	-316	-298	-285	-272	-256	-238	-222	-199	-177	-158	-143	-133	-126	-121	-110	-102	-100	-94.63	-89.25
Additional Paid-In Capital	1.4%	408	402	395	371	366	362	356	353	308	304	295	271	171	169	138	137	129	107	106	98.00	98.00
Shares Outstanding	-0.1%	27.00	27.00	27.00	26.00	26.00	23.00	22.00	20.00	17.00	16.00	16.00	14.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	98.00	-	-	-	132	-	-	-	308	-	-	-	26.00	-	-	-	20.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	15.1%	-7,341	-8,645	-9,636	-4,757	-7,941	-10,695	-11,115	-18,094	-15,136	-12,435	-12,306	-10,532	-6,760	-3,792	-2,639	-4,545	-2,852	-3,382	-5,502	-3,989	-3,439
Cashflow From Investing	70.5%	-83.00	-281	4,179	-4,362	-59.00	-174	-159	-181	-444	-97.00	-5,053	-2,540	-1,549	-30.00	-15.00	-28.00	-26.00	-15.00	-27.00	-45.00	-92.00
Cashflow From Financing	-100.0%	-	204	19,438	-1,389	265	-	23,652	38,023	-	-	55.00	65,711	-	27,548	-	-	18,689	-	6,558	-	3,023
Buy Backs	-	-	-	-	-	-	-	134	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

DRIO Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Total revenues	$ 20,352	$ 27,656
Total cost of revenues	14,368	18,001
Gross profit	5,984	9,655
Operating expenses:
Research and development	20,248	19,649
Sales and marketing	23,785	30,323
General and administrative	18,140	16,493
Total operating expenses	62,173	66,465
Operating loss	56,189	56,810
Total financial expenses, net	3,174	5,379
Loss before taxes	59,363	62,189
Income Tax	64	4
Net loss	59,427	62,193
Other comprehensive loss:
Deemed dividend	4,084	1,643
Net loss attributable to shareholders	$ 63,511	$ 63,836
Net loss per share:
Basic net loss per share of common stock	$ 1.93	$ 2.54
Diluted net loss per share of common stock	$ 1.93	$ 2.54
Weighted average number of Common Stock used in computing basic net loss per share	28,371,979	23,635,038
Weighted average number of Common Stock used in computing diluted net loss per share	28,371,979	23,635,038
Services
Total revenues	$ 13,084	$ 17,859
Total cost of revenues	4,679	5,324
Consumer hardware
Total revenues	7,268	9,797
Total cost of revenues	5,303	8,320
Amortization of acquired intangible assets
Total cost of revenues	$ 4,386	$ 4,357

DRIO Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
CURRENT ASSETS:
Cash and cash equivalents	$ 36,797	$ 49,357
Short-term restricted bank deposits	292	165
Trade receivables , net	3,155	6,416
Inventories	5,062	7,956
Other accounts receivable and prepaid expenses	2,024	1,630
Total current assets	47,330	65,524
NON-CURRENT ASSETS:
Deposits	6	6
Operating lease right of use assets	967	1,206
Long-term assets	143	111
Property and equipment, net	899	788
Intangible assets, net	5,404	9,916
Goodwill	41,640	41,640
Total non-current assets	49,059	53,667
Total assets	96,389	119,191
CURRENT LIABILITIES:
Trade payables	1,131	2,322
Deferred revenues	997	1,320
Operating lease liabilities	111	293
Other accounts payable and accrued expenses	6,300	6,592
Current maturity of long term loan	3,954	8,823
Total current liabilities	12,493	19,350
NON-CURRENT LIABILITIES
Operating lease liabilities	885	827
Long-term loan	24,591	18,105
Warrant liability	240	910
Other long-term liabilities	36	0
Total non-current liabilities	25,752	19,842
STOCKHOLDERS' EQUITY
Common stock of $0.0001 par value - authorized: 160,000,000 shares; issued and outstanding: 27,191,849 and 25,724,470 shares on December 31, 2023 and December 31, 2022, respectively	3	3
Preferred stock of $0.0001 par value - authorized: 5,000,000 shares; issued and outstanding: 18,959 and 3,567 shares on December 31, 2023 and December 31, 2022, respectively
Additional paid-in capital	407,502	365,846
Accumulated deficit	(349,361)	(285,850)
Total stockholders' equity	58,144	79,999
Total liabilities and stockholders' equity	$ 96,389	$ 119,191

About DarioHealth Corp

DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its user-centric multi-chronic condition digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company offers Dario Evolve, a metabolic solution to address metabolic health needs, such as diabetes, hypertension, and weight management; Dario Move to address most common MSK conditions; Dario Elevate, a behavioral health solution that optimizes access to evidence-based care; Dario One, a full suite of chronic condition management solution; and Dario blood glucose monitoring systems. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.

CEO	Mr. Erez Raphael
WEBSITE	dariohealth.com
INDUSTRY	Diagnostics & Research
EMPLOYEES	241

DarioHealth Corp Frequently Asked Questions

What is the ticker symbol for DarioHealth Corp? What does DRIO stand for in stocks?

DRIO is the stock ticker symbol of DarioHealth Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of DarioHealth Corp (DRIO)?

As of Tue Apr 30 2024, market cap of DarioHealth Corp is 41.81 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of DRIO stock?

You can check DRIO's fair value in chart for subscribers.

What is the fair value of DRIO stock?

You can check DRIO's fair value in chart for subscribers. The fair value of DarioHealth Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of DarioHealth Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for DRIO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is DarioHealth Corp a good stock to buy?

The fair value guage provides a quick view whether DRIO is over valued or under valued. Whether DarioHealth Corp is cheap or expensive depends on the assumptions which impact DarioHealth Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for DRIO.

What is DarioHealth Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 30 2024, DRIO's PE ratio (Price to Earnings) is -0.7 and Price to Sales (PS) ratio is 2.05. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. DRIO PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on DarioHealth Corp's stock?

In the past 10 years, DarioHealth Corp has provided -0.437 (multiply by 100 for percentage) rate of return.